Algernon Pharmaceuticals is focused on drug repurposing, which involves identifying new therapeutic uses for existing drugs that have a well-established safety profile but have not been marketed in major markets like the U.S. or Europe. This approach is designed to be cost-effective and efficient, allowing for quicker transitions into clinical trials compared to developing new chemical entities. The company is advancing several compounds through its pipeline, including NP-251 (Repirinast), originally developed for asthma, which is being repurposed for chronic kidney disease, and NP-120 (Ifenprodil), which has been acquired by a U.S. drug development company for treating chronic cough and idiopathic pulmonary fibrosis.

A significant focus of Algernon Pharmaceuticals is on the development of AP-188 (N,N-Dimethyltryptamine or DMT) through its subsidiary, Algernon NeuroScience. DMT is a naturally occurring psychedelic compound that is being investigated as a potential treatment for stroke and traumatic brain injury (TBI). The company is conducting a Phase 1 clinical trial in the Netherlands to assess the safety and pharmacokinetics of DMT, with plans for subsequent Phase 2 studies targeting acute ischemic stroke and TBI rehabilitation. DMT's mechanism of action involves promoting neuroplasticity and increasing brain-derived neurotrophic factor (BDNF), which are critical for recovery following brain injuries.

Canada

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF) is a clinical-stage pharmaceutical development company. Our unique drug repurposing strategy enables us to discover new therapeutic uses for existing drugs. This business model lowers investment, risk, and research periods while increasing active patent life.

Twitter: @AlgernonPharma
Facebook: @AlgernonPharmaceuticals

Algernon Pharmaceuticals

Company Details